查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1809919

射頻治療市場按成分、治療類別、腫瘤類型、適應症和最終用戶分類－全球預測，2025-2030

Radioembolization Therapy Market by Component, Treatment Category, Tumor Type, Application Procedure, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計射頻增強市場在 2024 年的價值將達到 10.9 億美元，在 2025 年成長至 11.5 億美元，到 2030 年將達到 15.4 億美元，複合年成長率為 5.90%。

主要市場統計數據
基準年2024年 10.9億美元
預計2025年 11.5億美元
預測年份 2030 15.4億美元
複合年成長率（%） 5.90%

射頻治療標誌著複雜肝癌病例先進管理的基石治療的出現

射頻消融術已成為複雜肝腫瘤患者的重要治療選擇。該治療方法基於數十年的放射學和介入創新，將放射性微球靶向輸送至肝血管系統，從而實現腫瘤局部照射，同時保護周圍健康組織。隨著其有效性和安全性不斷得到臨床證據的檢驗，射頻消融正從一種實驗性方法轉變為多模式腫瘤治療的基石。

面對技術創新和臨床突破，我們發現了影響射頻治療格局的關鍵轉折點

隨著介入放射學和核子醫學的融合，射頻治療的格局正在發生重大變化。顯像模式的進步，尤其是錐狀射束CT和SPECT-CT融合技術的整合，改善了即時視覺化和治療後劑量測定，使臨床醫生能夠以前所未有的精度客製化放射劑量。同時，基於玻璃、樹脂和聚合物的載體微球設計的改進提高了生物相容性和劑量輸送效率，標誌著向以患者為中心的個人化治療邁出了突破性的一步。

評估 2025 年美國關稅對射頻消融市場和供應鏈恢復策略的綜合影響

美國將於2025年對進口零件和同位素徵收關稅，這將為射頻治療市場帶來複雜的挑戰。專用導管、先進影像處理設備和專有微球技術等零件可能面臨關稅上調，從而增加醫療機構和設備製造商的採購成本。因此，供應鏈相關人員必須評估短期財務影響，同時制定策略，確保患者能夠負擔得起且獲得治療。

按成分、治療類別、腫瘤類型、適應症和最終用戶分類的關鍵細分洞察

深入探究市場區隔的細微差別，可以發現影響射頻療法應用的關鍵領域。從組件類別來看，介入耗材領域包括精密的導管輸送系統、高精度核子醫學相機、先進的放射性微球以及輔助X光成像平台，這些都對手術的成功至關重要。從治療方法類別來看，介入性耗材領域分為治癒性治療和安寧療護，治癒性治療方案針對早期惡性腫瘤，而安寧療護方案則著重於緩解症狀並改善晚期患者的生活品質。

了解美洲、歐洲、中東和非洲以及亞太地區射頻消融的區域動態

射頻治療的區域動態揭示了全球市場不同的應用和創新模式。在美洲，完善的報銷框架和廣泛的介入放射中心網路推動了穩定的手術量。北美醫療保健提供者通常是新型微球技術和影像整合的早期採用者，這反映出其在先進腫瘤干預措施方面創新投資的文化。同時，隨著區域醫療保健系統擴大複雜手術的診療能力，並在多中心臨床註冊方面開展合作以檢驗長期療效，拉丁美洲市場正呈現漸進式成長。

重點介紹產業領導者透過策略聯盟和技術投資推動射頻治療領域的創新、協作和競爭成長

射頻治療產業的進步正由一批涉足設備製造、同位素生產和臨床服務交付領域的先驅企業推動。一些成熟的介入治療公司正引領產業發展，建立策略聯盟，共同開發下一代微球平台，專注於增強放射性有效載荷並最佳化動態特性。同時，核子醫學專家正在與學術研究機構合作，改進劑量測定模型，並簡化新型示蹤同位素的核准。

制定可行的策略建議，以增強射頻治療的市場定位、營運效率和合作研究進展

為了充分利用射頻消融領域不斷發展的機遇，產業領導者應採取多方面的策略性舉措。首先，透過多元化的製造地和策略採購協議來最佳化供應鏈的彈性，可以緩解關稅相關的中斷，並保障關鍵零件的連續性。同時投資數位庫存管理和預測性採購分析，可以進一步提升營運敏捷性。

發現支持資料收集、檢驗流程和分析框架的綜合調查方法，以獲得深入的市場洞察

我們的調查方法將嚴謹的第一級和第二級研究與強大的分析框架相結合，以提供全面的市場覆蓋和可靠的洞察。首先，我們進行了廣泛的文獻綜述，涵蓋同行評審期刊、監管備案文件、臨床試驗資料庫和專有產業報告，以建立基礎知識庫。此外，我們還對已發表的專利文獻和設備註冊記錄進行了深入分析，以追蹤技術趨勢和競爭動態。

關於射頻消融市場格局的演變軌跡、臨床影響和策略要務的總結性評論

我們對射頻消融市場的研究揭示了快速的技術發展、不斷變化的政策環境和動態的臨床通訊協定之間的交匯。導管系統的成熟、新型微球製劑的出現以及數位化規劃工具的整合，共同表明該領域將持續創新。同時，關稅壓力和監管複雜性要求我們採取適應性策略，以維持供應鏈的完整性和成本效益。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章市場動態

  • 射頻消融術合併查核點抑制劑在肝癌治療的應用日益增多
  • 擴大轉移性大腸直腸腫瘤和神經內分泌腫瘤射頻消融的適應症
  • 先進的成像和劑量測定軟體的整合增強了個人化治療計劃
  • 钬-166微球擴大了腫瘤標靶射頻治療的選擇
  • 亞太地區放射栓塞設備監管核准其滲透至新興市場
  • 介入放射學與腫瘤學公司之間的策略聯盟加速微球創新
  • 門診放射栓塞通訊協定可減少住院時間並使治療更具成本效益
  • 人工智慧預測模型改善了射頻治療的患者選擇和結果預測
  • 玻璃微球製造技術的進步可以提高特定活性和劑量傳遞的準確性。
  • 專注於產生真實世界證據來證明長期安全性和有效性

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章射頻治療市場（按組件）

  • 導管
  • 核子醫學設備
  • 放射性微球
  • X光設備

第9章射頻治療市場（依治療類別）

  • 復原
  • 寬慰

第 10 章射頻治療市場（依腫瘤類型）

  • 轉移性肝癌
  • 原發性肝癌

第 11 章射頻治療市場（按適應症）

  • 肝臟腫瘤
  • 小葉治療
  • 部分治療

第 12 章射頻治療市場（按最終用戶）

  • 門診手術中心
  • 癌症研究所
  • 醫院

13.美洲射頻治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

第 14 章歐洲、中東和非洲射頻治療市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

15. 亞太地區射頻治療市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Cook Medical Inc.
    • Boston Scientific Corporation
    • Bayer AG
    • Becton Dickinson & Company
    • Elekta AB
    • Fortis Healthcare Limited
    • Hamilton Health Sciences
    • Mayo Clinic Health System
    • Merit Medical Systems, Inc.
    • Nordion Inc.
    • Northwestern Memorial HealthCare.
    • Radiological Society of North America, Inc.
    • Siemens AG
    • Sirtex Medical Pty Ltd
    • Stryker Corporation
    • Terumo Corporation
    • United HealthCare Services, Inc
    • Medtronic plc

第17章 研究人工智慧

第18章 研究統計

第19章 研究聯絡人

第20章 研究報導

第21章 附錄

Product Code: MRR-562E923A9568

The Radioembolization Therapy Market was valued at USD 1.09 billion in 2024 and is projected to grow to USD 1.15 billion in 2025, with a CAGR of 5.90%, reaching USD 1.54 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.09 billion
Estimated Year [2025] USD 1.15 billion
Forecast Year [2030] USD 1.54 billion
CAGR (%) 5.90%

Charting the Emergence of Radioembolization Therapy as a Cornerstone Treatment Advancing Precision Management of Complex Liver Cancer Cases

Radioembolization therapy has emerged as a vital treatment option for patients confronting complex liver malignancies. Building on decades of radiologic and interventional innovations, this modality integrates targeted delivery of radioactive microspheres into the hepatic vasculature, allowing for localized irradiation of tumors while preserving surrounding healthy tissue. As clinical evidence continues to validate its efficacy and safety profile, radioembolization has transitioned from an experimental approach to a foundational component of multidisciplinary oncology care.

Against this backdrop of evolving clinical practice, understanding the market dynamics that govern the adoption and diffusion of radioembolization therapy is essential. Technological refinements in catheter systems, the development of next-generation radioisotopes, and enhanced imaging guidance tools have collectively elevated procedural precision and patient outcomes. Yet, these advancements also introduce complexities in supply chain management, regulatory compliance, and stakeholder alignment. Therefore, a rigorous exploration of industry forces, regulatory landscapes, and innovation pipelines is necessary to navigate the competitive and clinical terrain effectively.

This executive summary distills the most salient developments shaping the radioembolization ecosystem, offering decision-makers a clear perspective on transformative trends, segmentation insights, regional variances, and actionable recommendations. By contextualizing the therapy's maturation within broader shifts in healthcare delivery and reimbursement, we aim to equip industry leaders, clinical practitioners, and strategic investors with the knowledge needed to capitalize on emerging opportunities and address pivotal challenges.

Unveiling Pivotal Transformative Shifts Reshaping the Radioembolization Therapy Landscape in the Face of Technological Innovation and Clinical Breakthroughs

The radioembolization landscape is undergoing profound transformation as convergence between interventional radiology and nuclear medicine intensifies. Advancements in imaging modalities, particularly the integration of cone-beam CT and SPECT-CT fusion, have elevated real-time visualization and post-treatment dosimetry, enabling clinicians to tailor radiation doses with unprecedented accuracy. Concurrently, the refinement of microsphere design-spanning glass, resin, and emerging polymer-based carriers-has enhanced biocompatibility and dose delivery efficiency, marking a pivotal shift from one-size-fits-all approaches toward patient-centric therapy customization.

Transitional breakthroughs in catheter engineering have also streamlined vascular access and prevented non-target embolization, reducing procedure times and minimizing adverse events. In parallel, the introduction of combined modality protocols, which integrate radioembolization with systemic immunotherapies or intra-arterial chemotherapy, has demonstrated synergistic antitumor effects, broadening the technique's therapeutic scope. These multidisciplinary regimens underscore a move toward precision oncology strategies that leverage locoregional interventions to complement systemic treatments.

Moreover, digital health solutions are reshaping peri-procedural planning and outcome monitoring. Cloud-based analytics and artificial intelligence-driven algorithms are now used to predict vascular anatomy and optimize particle distribution. Consequently, stakeholders from device manufacturers to clinical centers are investing in end-to-end digital workflows, reflecting a transformative trend in how radioembolization services are conceived, delivered, and evaluated.

Assessing the Compounded Consequences of 2025 United States Tariffs on the Radioembolization Therapy Market and Supply Chain Resilience Strategies

The imposition of tariffs by the United States on imported components and isotopes in 2025 presents a complex challenge for the radioembolization market. Components such as specialized catheters, advanced imaging devices, and proprietary microsphere technologies now face increased duties, which can elevate procurement costs for healthcare providers and device manufacturers. As a result, supply chain stakeholders must assess the short-term fiscal impacts while devising strategies that preserve therapy affordability and accessibility for patients.

In response, several manufacturers have explored near-shoring production or establishing additional domestic manufacturing lines to mitigate cost pressures. These ventures require substantial capital investments and regulatory approvals, yet they present an opportunity to fortify supply chain resilience. At the same time, clinical centers are negotiating long-term purchasing agreements and exploring collaborative procurement frameworks to stabilize pricing.

Meanwhile, emerging local isotope production initiatives are gaining traction as a buffer against international tariff volatility. Although these domestic projects may not yet achieve full-scale output parity with established global suppliers, they underscore a strategic pivot toward self-sufficiency. Ultimately, navigating the tariff landscape demands a balanced approach that harmonizes cost containment, regulatory compliance, and uninterrupted access to critical radioembolization technologies.

Extracting Key Segmentation Insights to Illuminate Component, Treatment Category, Tumor Type, Application Procedure, and End-User Dynamics

Delving into the nuances of market segmentation reveals pivotal areas shaping radioembolization therapy adoption. Examining component categories, the sphere of interventional consumables spans sophisticated catheter delivery systems, high-precision nuclear medicine cameras, advanced radioactive microspheres, and supplementary X-ray imaging platforms, each integral to procedural success. Transitioning to treatment categorizations, the divide between curative and palliative intent underscores divergent clinical pathways, with curative protocols targeting early-stage malignancies and palliative regimens focusing on symptom relief and quality of life enhancement for advanced disease stages.

The segmentation by tumor type further refines market understanding, as practices for addressing metastatic liver cancer diverge significantly from those treating primary hepatocellular carcinoma. Distinct tumor biology, patient comorbidities, and response profiles guide clinical decision-making and device selection criteria. In the context of application procedures, practitioners differentiate between whole liver interventions, lobar therapy focused on a specific hepatic lobe, and highly targeted segmental therapy aiming at localized tumor nodules. This granularity enables personalized treatment planning and optimizes risk-benefit assessments.

Equally important is the end-user segmentation, where ambulatory surgical centers emphasize cost-efficient procedural throughput, cancer research institutes prioritize integration with clinical trials and experimental protocols, and hospitals leverage comprehensive multidisciplinary teams to deliver complex interdepartmental care. By synthesizing insights across component, treatment category, tumor type, application procedure, and end-user dimensions, stakeholders can pinpoint strategic priorities for innovation, market expansion, and targeted commercialization efforts.

Decoding Regional Dynamics in the Radioembolization Therapy Domain Across Americas, Europe Middle East & Africa, and Asia-Pacific Specificities

Regional dynamics in radioembolization therapy reveal differentiated patterns of adoption and innovation across global markets. In the Americas, established reimbursement frameworks and an extensive network of interventional radiology centers drive consistent procedural volumes. North American providers are often early adopters of novel microsphere technologies and imaging integrations, reflecting a culture of innovation and investment in advanced oncologic interventions. Meanwhile, Latin American markets exhibit incremental growth as regional healthcare systems expand capacity for complex procedures and collaborate on multicenter clinical registries to validate long-term outcomes.

Transitioning to Europe, Middle East & Africa, diverse regulatory environments and heterogeneous healthcare infrastructures present both challenges and opportunities. In Western Europe, centralized health technology assessments guide procurement strategies, often prioritizing cost-effectiveness data and real-world evidence to support therapy adoption. In contrast, emerging markets across the Middle East and Africa are gradually enhancing specialized treatment centers, fostering partnerships with global manufacturers to establish training programs and supply networks.

The Asia-Pacific region manifests robust growth trajectories, driven by aging populations and rising cancer incidence rates. Countries such as Japan and South Korea lead in clinical research, exploring advanced dosimetry protocols and combination therapy trials. Meanwhile, rapidly developing markets in Southeast Asia and Australia are scaling up institutional capabilities, investing in workforce training and forging public-private alliances to broaden patient access to radioembolization therapy across urban and regional centers.

Highlighting Leading Industry Players Driving Innovation, Collaboration, and Competitive Growth in Radioembolization Therapy Through Strategic Alliances and Technology Investments

Industry progress in radioembolization therapy is propelled by a select cohort of pioneering companies that span device manufacturing, isotope production, and clinical service delivery. Leading the pack, established interventional entities have secured strategic collaborations to co-develop next-generation microsphere platforms, focusing on enhanced radioactive payloads and optimized hydrodynamic properties. At the same time, nuclear medicine specialists collaborate with academic research institutions to refine dosimetric models and streamline approvals for novel tracer isotopes.

Concurrently, a wave of emerging players has introduced complementary products that address procedural bottlenecks. Some firms specialize in advanced catheter tip designs that minimize vascular trauma, while others deliver integrated imaging solutions that merge multiple modalities within a unified operating suite. These advancements are frequently supported by joint ventures, distribution agreements, and technology transfer partnerships designed to accelerate global market penetration.

Moreover, several companies have adopted a holistic approach to customer engagement, offering comprehensive training programs, digital planning tools, and post-procedure support services. By cultivating these ecosystem partnerships, market leaders reinforce their competitive positioning and pave the way for iterative improvements that benefit clinicians and patients alike.

Formulating Actionable Strategic Recommendations to Enhance Market Positioning, Operational Efficiency, and Collaborative Advancement in Radioembolization Therapy

To capitalize on the evolving landscape of radioembolization therapy, industry leaders should pursue a multifaceted strategic agenda. First, optimizing supply chain resilience through diversified manufacturing footprints and strategic sourcing agreements will mitigate tariff-related disruptions and safeguard continuity of critical components. Parallel investments in digital inventory management and predictive procurement analytics can further enhance operational agility.

Second, fostering cross-disciplinary collaboration between interventional radiologists, nuclear medicine specialists, and oncologists is crucial. Establishing joint research consortia and multicenter clinical trials will generate robust evidence for combination therapies, thereby strengthening reimbursement cases and accelerating regulatory approvals. In addition, integrating real-world data capture into routine practice will support iterative refinements of procedural protocols and patient selection criteria.

Third, enhancing end-user engagement through tailored educational programs and decision-support tools will drive broader adoption. By developing virtual training simulators and outcome benchmarking dashboards, stakeholders can equip clinical teams with the knowledge and confidence to deliver advanced radioembolization services. Finally, expanding partnerships with payers and health technology assessment bodies to demonstrate long-term value and cost-effectiveness will facilitate more predictable reimbursement pathways and unlock new markets for sustainable growth.

Elucidating the Comprehensive Research Methodology Underpinning Data Collection, Validation Processes, and Analytical Frameworks for In-Depth Market Insights

Our research methodology combines rigorous primary and secondary data collection with robust analytical frameworks to ensure comprehensive market coverage and credible insights. Initially, an extensive literature review encompassed peer-reviewed journals, regulatory filings, clinical trial databases, and proprietary industry reports to establish a foundational knowledge base. This was complemented by an exhaustive analysis of publicly available patent documents and device registry records to track technological trends and competitive developments.

Simultaneously, primary research efforts engaged over two hundred stakeholders across the ecosystem, including interventional radiologists, nuclear medicine experts, procurement specialists, and regulatory authorities. Structured interviews and in-depth surveys captured qualitative perspectives on procedural workflows, adoption barriers, and emerging clinical practices. To validate these insights, data triangulation techniques compared multiple information sources, identifying convergent patterns and resolving discrepancies.

Quantitative modeling techniques were applied to cost structures, pricing trends, and utilization rates, while scenario analyses explored potential impacts of tariff policies, regulatory changes, and technological breakthroughs. Throughout the process, a panel of senior clinicians and industry veterans provided continuous input, ensuring that assumptions reflected real-world practice and that findings were grounded in current clinical and commercial realities. This integrated approach delivers a transparent, replicable framework for understanding the radioembolization therapy market in its full complexity.

Drawing Conclusive Perspectives on the Evolutionary Trajectory, Clinical Impact, and Strategic Imperatives of the Radioembolization Therapy Market Landscape

Our examination of the radioembolization therapy market underscores an intersection of rapid technological evolution, shifting policy environments, and dynamic clinical protocols. The maturation of catheter systems, the advent of novel microsphere formulations, and the integration of digital planning tools collectively signify a sector poised for continued innovation. At the same time, tariff pressures and regulatory intricacies demand adaptive strategies to maintain supply chain integrity and cost efficiencies.

Segmentation analysis reveals that differentiated approaches to component selection, treatment intent, tumor biology, procedural techniques, and care settings will shape competitive landscapes and patient access. Regional variances highlight the necessity of tailored adoption roadmaps, reflecting localized reimbursement frameworks, clinical preferences, and infrastructure capabilities. Furthermore, collaboration among device manufacturers, clinical centers, and research consortia emerges as a critical catalyst for advancing evidence-based practice and accelerating market expansion.

Looking ahead, the capacity to harness real-world data, foster interdisciplinary partnerships, and demonstrate long-term value through rigorous health economics assessments will determine which stakeholders lead the next phase of growth. Ultimately, the strategic imperatives identified in this report provide a clear blueprint for navigating complexity, driving innovation, and delivering enhanced patient outcomes in the radioembolization therapy domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Growing use of radioembolization combined with checkpoint inhibitors in liver cancer management
  • 5.2. Expansion of indications for metastatic colorectal and neuroendocrine tumor radioembolization therapies
  • 5.3. Integration of advanced imaging and dosimetry software enhances personalized treatment planning
  • 5.4. Adoption of holmium-166 microspheres broadens radioembolization options for tumor targeting
  • 5.5. Regulatory approval of radioembolization devices in Asia Pacific drives emerging market penetration
  • 5.6. Strategic alliances between interventional radiology and oncology firms accelerate microsphere innovation
  • 5.7. Outpatient radioembolization protocols reduce hospital stays and drive procedural cost efficiencies
  • 5.8. AI-driven predictive modeling improves patient selection and outcome forecasting in radioembolization therapy
  • 5.9. Advances in glass microsphere manufacturing enhance specific activity and dose delivery precision
  • 5.10. Increasing focus on real-world evidence generation to demonstrate long-term safety and efficacy profiles

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Radioembolization Therapy Market, by Component

  • 8.1. Introduction
  • 8.2. Catheters
  • 8.3. Nuclear Medicine Equipment
  • 8.4. Radioactive Microspheres
  • 8.5. X-Ray Equipment

9. Radioembolization Therapy Market, by Treatment Category

  • 9.1. Introduction
  • 9.2. Curative
  • 9.3. Palliative

10. Radioembolization Therapy Market, by Tumor Type

  • 10.1. Introduction
  • 10.2. Metastatic Liver Cancer
  • 10.3. Primary Liver Cancer

11. Radioembolization Therapy Market, by Application Procedure

  • 11.1. Introduction
  • 11.2. Liver Tumour
  • 11.3. Lobar Therapy
  • 11.4. Segmental Therapy

12. Radioembolization Therapy Market, by End-User

  • 12.1. Introduction
  • 12.2. Ambulatory Surgical Centers
  • 12.3. Cancer Research Institutes
  • 12.4. Hospitals

13. Americas Radioembolization Therapy Market

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. Argentina

14. Europe, Middle East & Africa Radioembolization Therapy Market

  • 14.1. Introduction
  • 14.2. United Kingdom
  • 14.3. Germany
  • 14.4. France
  • 14.5. Russia
  • 14.6. Italy
  • 14.7. Spain
  • 14.8. United Arab Emirates
  • 14.9. Saudi Arabia
  • 14.10. South Africa
  • 14.11. Denmark
  • 14.12. Netherlands
  • 14.13. Qatar
  • 14.14. Finland
  • 14.15. Sweden
  • 14.16. Nigeria
  • 14.17. Egypt
  • 14.18. Turkey
  • 14.19. Israel
  • 14.20. Norway
  • 14.21. Poland
  • 14.22. Switzerland

15. Asia-Pacific Radioembolization Therapy Market

  • 15.1. Introduction
  • 15.2. China
  • 15.3. India
  • 15.4. Japan
  • 15.5. Australia
  • 15.6. South Korea
  • 15.7. Indonesia
  • 15.8. Thailand
  • 15.9. Philippines
  • 15.10. Malaysia
  • 15.11. Singapore
  • 15.12. Vietnam
  • 15.13. Taiwan

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Cook Medical Inc.
    • 16.3.2. Boston Scientific Corporation
    • 16.3.3. Bayer AG
    • 16.3.4. Becton Dickinson & Company
    • 16.3.5. Elekta AB
    • 16.3.6. Fortis Healthcare Limited
    • 16.3.7. Hamilton Health Sciences
    • 16.3.8. Mayo Clinic Health System
    • 16.3.9. Merit Medical Systems, Inc.
    • 16.3.10. Nordion Inc.
    • 16.3.11. Northwestern Memorial HealthCare.
    • 16.3.12. Radiological Society of North America, Inc.
    • 16.3.13. Siemens AG
    • 16.3.14. Sirtex Medical Pty Ltd
    • 16.3.15. Stryker Corporation
    • 16.3.16. Terumo Corporation
    • 16.3.17. United HealthCare Services, Inc
    • 16.3.18. Medtronic plc

17. ResearchAI

18. ResearchStatistics

19. ResearchContacts

20. ResearchArticles

21. Appendix

LIST OF FIGURES

  • FIGURE 1. RADIOEMBOLIZATION THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 16. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 18. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. ASIA-PACIFIC RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. RADIOEMBOLIZATION THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. RADIOEMBOLIZATION THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 25. RADIOEMBOLIZATION THERAPY MARKET: RESEARCHAI
  • FIGURE 26. RADIOEMBOLIZATION THERAPY MARKET: RESEARCHSTATISTICS
  • FIGURE 27. RADIOEMBOLIZATION THERAPY MARKET: RESEARCHCONTACTS
  • FIGURE 28. RADIOEMBOLIZATION THERAPY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. RADIOEMBOLIZATION THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CATHETERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY NUCLEAR MEDICINE EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY NUCLEAR MEDICINE EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY RADIOACTIVE MICROSPHERES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY RADIOACTIVE MICROSPHERES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY X-RAY EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY X-RAY EQUIPMENT, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CURATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CURATIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PALLIATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PALLIATIVE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY METASTATIC LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY METASTATIC LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PRIMARY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY PRIMARY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LIVER TUMOUR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LIVER TUMOUR, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LOBAR THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY LOBAR THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY SEGMENTAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY SEGMENTAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 48. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 49. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 50. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 51. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 52. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 53. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 54. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 55. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 56. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 57. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. AMERICAS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 59. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 60. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 61. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 62. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 63. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 64. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 65. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 66. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 67. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 68. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 69. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 70. UNITED STATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 71. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 72. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 73. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 74. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 75. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 77. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 78. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 79. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 80. CANADA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 81. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 82. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 83. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 84. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 85. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 88. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 89. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 90. MEXICO RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 91. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 92. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 93. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 94. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 95. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 96. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 97. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 98. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 99. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 100. BRAZIL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 101. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 102. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 103. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 104. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 105. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 108. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 109. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 110. ARGENTINA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED KINGDOM RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 133. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 134. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 135. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 136. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 137. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 139. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 140. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 141. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. GERMANY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 143. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 144. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 145. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 146. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 147. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 150. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 151. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 152. FRANCE RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 153. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 154. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 155. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 156. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 157. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 159. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 160. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 161. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 162. RUSSIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 163. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 164. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 165. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 166. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 167. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 170. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 171. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 172. ITALY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 173. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 174. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 175. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 176. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 177. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 179. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 180. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 181. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 182. SPAIN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 193. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 194. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 196. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 200. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. SAUDI ARABIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 204. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 206. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 210. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 212. SOUTH AFRICA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 213. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 214. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 215. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 216. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 217. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 219. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 220. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 221. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 222. DENMARK RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 223. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 224. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 225. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 226. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 227. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 230. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 232. NETHERLANDS RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 233. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 234. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 235. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 236. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 237. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 239. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 240. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 241. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 242. QATAR RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 243. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 244. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 245. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 246. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 247. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 250. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 251. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 252. FINLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 253. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 254. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 255. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 256. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 257. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 259. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 260. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 261. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 262. SWEDEN RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 263. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 264. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 265. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 266. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 267. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 270. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 271. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 272. NIGERIA RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 273. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 274. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 275. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 276. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 277. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 279. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 280. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 281. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 282. EGYPT RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 283. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 284. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 285. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 286. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 287. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 290. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 291. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 292. TURKEY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 293. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 294. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 295. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 296. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 297. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 299. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 300. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 301. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 302. ISRAEL RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 303. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 304. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 305. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 306. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 307. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 309. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 310. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 311. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 312. NORWAY RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 313. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 314. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY COMPONENT, 2025-2030 (USD MILLION)
  • TABLE 315. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 316. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TREATMENT CATEGORY, 2025-2030 (USD MILLION)
  • TABLE 317. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY TUMOR TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2018-2024 (USD MILLION)
  • TABLE 320. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY APPLICATION PROCEDURE, 2025-2030 (USD MILLION)
  • TABLE 321. POLAND RADIOEMBOLIZATION THERAPY MARKET SIZE, BY END-USER, 2018-2024 (USD MIL